Drugs Stocks On The Rise With Help From 5 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 116 points (0.8%) at 15,038 as of Monday, Sept. 9, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 2,262 issues advancing vs. 646 declining with 106 unchanged.

The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 11.5%, Incyte ( INCY), up 5.5% and Novo Nordisk A/S ( NVO), up 1.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $1.84 (2.5%) to $74.54 on heavy volume. Thus far, 1.2 million shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $72.49-$74.54 after having opened the day at $72.50 as compared to the previous trading day's close of $72.70.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.9 billion and is part of the health care sector. Shares are up 47.8% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $2.03 (2.6%) to $81.02 on light volume. Thus far, 446,738 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $78.25-$81.18 after having opened the day at $79.13 as compared to the previous trading day's close of $78.99.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.2 billion and is part of the health care sector. Shares are up 88.5% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $6.71 (2.5%) to $274.28 on average volume. Thus far, 461,730 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 751,500 shares. The stock has ranged in price between $267.91-$275.48 after having opened the day at $267.91 as compared to the previous trading day's close of $267.57.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $26.0 billion and is part of the health care sector. Shares are up 56.4% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is up $0.92 (0.6%) to $147.89 on average volume. Thus far, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $147.06-$148.50 after having opened the day at $147.06 as compared to the previous trading day's close of $146.97.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $59.9 billion and is part of the health care sector. Shares are up 85.5% year to date as of the close of trading on Friday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.10 (1.8%) to $62.22 on light volume. Thus far, 2.4 million shares of Gilead exchanged hands as compared to its average daily volume of 8.6 million shares. The stock has ranged in price between $61.08-$62.27 after having opened the day at $61.08 as compared to the previous trading day's close of $61.12.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $93.5 billion and is part of the health care sector. Shares are up 66.4% year to date as of the close of trading on Friday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists